Amgen's Financial Triumph in Q1 2025

Amgen Inc. has kicked off 2025 with a remarkable financial performance, announcing a 9% increase in revenue to $8.1 billion for the first quarter, slightly surpassing market expectations.

Profitability on the Rise

The company reported a GAAP net income of $1.7 billion, or $3.20 per diluted share, a significant turnaround from the net loss of $113 million, or $0.21 per share, in the same period last year. Additionally, GAAP operating income saw a 20% year-on-year increase to $1.2 billion.

Leadership's Confidence in Growth

"Our products have seen strong global demand this quarter. With successful new product launches and promising Phase 3 trial results, we are optimistic about our long-term growth trajectory," stated CEO Robert Bradway.

Market Response

Following the announcement, Amgen shares experienced a 0.57% uptick in after-hours trading, reflecting investor confidence in the company's financial health and future prospects.